Protagonist Therapeutics Raises $40 MillionTo Advance IBD Oral Therapy Development

Protagonist Therapeutics Raises $40 MillionTo Advance IBD Oral Therapy Development
Protagonist Therapeutics, Inc., a company that specializes in advancing novel, orally-stable peptide treatments for gastrointestinal diseases and disorders, has just closed a $40 million Series C financing. The investment will fund continued advancement of the company’s experimental therapy PTG-100 for Inflammatory Bowel Disorder. “We are pleased with the strong support received from a broad cross section of

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *